The Germany Biosurgery Market was valued at $796.3 Million in 2025 and projected to reach to $1025.5 Million by 2030, representing a compound annual growth rate of 5.2%. Germany's biosurgery market is poised for sustained growth through 2030, supported by increasing surgical procedures, aging demographics, and rising demand for advanced hemostatic solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Germany's biosurgery market is valued at $796.3 million in 2025, with projected growth to $1,025.5 million by 2030, reflecting steady expansion in the European healthcare sector.
Germany's well-established medical device ecosystem, stringent quality standards, and high surgical volumes create an ideal environment for biosurgery product adoption and innovation.
Strong reimbursement policies from German statutory health insurance systems support widespread adoption of hemostatic agents and tissue sealants across surgical specialties.
Germany maintains a dominant position in the European biosurgery market, driven by leading medical device manufacturers, research institutions, and surgeon expertise in minimally invasive techniques.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Bone-graft substitutes, surgical sealants & adhesives, adhesion barriers, staple-line reinforcement, soft-tissue attachments, and hemostatic agents for hemostasis, tissue sealing, adhesion prevention, and tissue repair in surgical procedures. | Advanced hemostasis, minimized risk of leaks and bleeding, improved tissue handling, and effective adhesion prevention. Ethicon’s powered stapling and energy devices deliver enhanced sealing, less tissue slippage, and optimized surgical recovery. |
|
|
Biosurgery portfolio includes hemostats and sealants, adhesion barrier for preventing adhesions; and suture line reinforcement and sealing in cardiovascular and general surgery. | Rapid surgical hemostasis, effective adhesion reduction, strong, consistent tissue sealing, broad multi-specialty versatility, and clinically proven reduction in postoperative complications and optimized surgical workflow. |
|
|
Polymeric sealants, biological adhesives, skin and tissue closure products, and staple-line reinforcement agents for wound closure, spinal, cranial, and complex general surgery. | Enables rapid, needle-free wound closure, strong adhesion even in high-tension and moist environments, reduced CSF and other fluid leaks, and lower risk of infection. Enables sutureless procedures and improved cosmetic outcomes with robust tissue support. |
|
|
Synthetic and allograft bone grafts, staple-line reinforcement, soft-tissue attachments, dural sealants, and topical adhesives for craniofacial, spine, orthopaedic, and trauma applications. | Excellent osteointegration, reliable watertight dural sealing (99% CSF leak prevention), absorbable biomaterials for long-term regeneration, and reduced need for autograft harvesting all supporting faster healing and complication risk reduction. |
|
|
Biosurgery portfolio includes hemostatic agents, surgical sealants, absorbable sponges, and soft-tissue reinforcement for bleeding control and tissue closure used in open and minimally invasive surgeries. | Accelerates natural clotting, delivers rapid, reliable hemostasis, reduces surgical air leaks, is easy to use even in complex fields, and offers thrombin-free, 100% plant-based and collagen-based options proven safe and effective in a wide range of specialties |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | BONE MORPHOGENETIC PROTEINS (Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 6.4% from 2025 to 2030 |
| Largest Segment | HOSPITALS (End User) |
| Market Size Base Year (Billions) | ~USD 15.83 (2025) |
| Revenue Forecast (Billions) | ~USD 21.59 (2030) |
| Segments Covered | Type, Origin, Application, End User, Product |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| AMBULATORY SURGICAL CENTERS | 93 | 97.8 | 104 | 110.7 | 118 | 126 | 134.8 | 144.5 | 6.8 |
| CLINICS | 124.3 | 129.7 | 136.7 | 144.3 | 152.6 | 161.6 | 171.4 | 182.2 | 5.9 |
| HOSPITALS | 468.3 | 483.5 | 504.4 | 526.9 | 551.3 | 577.7 | 606.5 | 637.6 | 4.8 |
| OTHER END USERS | 48.5 | 49.5 | 51.1 | 52.8 | 54.7 | 56.7 | 58.9 | 61.2 | 3.7 |
| TOTAL | 734.1 | 760.5 | 796.3 | 834.7 | 876.6 | 922 | 971.6 | 1025.5 | 5.2 |
Germany's biosurgery market is valued at $796.3 million in 2025 and is expected to reach $1,025.5 million by 2030.
Germany's biosurgery market is growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2030.
Key growth drivers in Germany include advanced healthcare infrastructure, increasing demand for minimally invasive procedures, an aging population, robust reimbursement frameworks, and strong clinical evidence requirements supporting product adoption.
Germany maintains a strong position within the European biosurgery sector due to its advanced healthcare system, high surgical volumes, and favorable regulatory environment that supports innovation and product launches.
Germany shows strong demand for hemostatic agents, tissue sealants, and advanced wound management products, particularly in minimally invasive surgical applications across multiple specialties.
The study involved major activities in estimating the current market size for the biosurgery market. Exhaustive secondary research was done to collect information on the biosurgery industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Biosurgery market.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), International Trade Administration (ITA), Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global biosurgery market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the biosurgery market. The primary sources from the demand side include ambulatory surgical centers, hospitals, Clinics, and other end users. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*C-level primaries include CEOs, CFOs, COOs, and VPs.
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global biosurgery market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the global biosurgery market was split into various segments and sub-segments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After arriving at the global biosurgery market's overall size through the methodology mentioned above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Biosurgery products are essential in surgical procedures, aiding in the repair of damaged tissues and bones. Surgeons utilize these products to stabilize skin, internal organs, and blood vessels, ensuring hemostasis and tissue integrity after injury or surgery. Key types include surgical sealants, hemostatic agents, adhesion barriers, soft-tissue attachments, bone-graft substitutes, and staple-line reinforcement agents, all designed to enhance healing and prevent complications.
Full forecast, segment splits, and company analysis for all Biosurgery Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report